Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
Moderna shares extended a sharp 2026 rally, reviving investor questions about whether mRNA leadership is translating into relative strength versus older vaccine players such as Pfizer and rival developer Novavax.
THE APEX TIMES
THE APEX TIMES
In remarks reported by Yahoo Finance, Pfizer’s chief executive suggested the company could return to high-single-digit growth, a sign investors may be underestimating how quickly the business can stabilize.
THE APEX TIMES
A fresh market commentary points to Eli Lilly’s strong momentum, while warning that the stock’s price may already reflect a lot of good news, leaving less room for error.
THE APEX TIMES
Early clinical results for a JAK inhibitor Lilly acquired via its Ajax deal showed encouraging effects in patients with hard-to-treat myelofibrosis, a development analysts say could intensify competition for Incyte’s Jakafi.
THE APEX TIMES
With COVID-19 vaccine revenue already in decline and investors looking ahead to a patent cliff, the question for Pfizer’s shares is whether the company’s pipeline and strategic plan can close a widening earnings gap.
THE APEX TIMES
A Yahoo Finance item says Pfizer shares (PFE) have drawn unusually heavy investor attention on Zacks.com, prompting a checklist-style look at what traders typically monitor next.
THE APEX TIMES
CVS Health’s Aetna says its upgraded automated claims workflow can reduce the time it takes to process health insurance claims, a move designed to improve member and provider experiences.
THE APEX TIMES
The health-care company says the funding is aimed at strengthening its U.S. operations tied to its vision segment and supporting long-term manufacturing capacity.
THE APEX TIMES
The TV host highlighted UnitedHealth Group as investors rotated toward lower-volatility healthcare names, praising the company’s leadership in a segment on Mad Money.
